NCT03336346View on ClinicalTrials.gov

Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana

CompletedOBSERVATIONAL
Enrollment

148

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

October 30, 2019

Study Completion Date

December 11, 2019

Conditions
Contraceptive UsageHIV InfectionsDrug Interaction
Interventions
DRUG

dolutegravir

HIV integrase strand transfer inhibitor used in combination ART

DEVICE

ENG implant

Reversible contraception implant

DRUG

Efavirenz

non-nucleoside reverse transcriptase inhibitor used in combination ART

Trial Locations (1)

Unknown

Botswana-UPenn Partnership, Gaborone

All Listed Sponsors
lead

Columbia University

OTHER

NCT03336346 - Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana | Biotech Hunter | Biotech Hunter